
Annual report 2025
added 02-03-2026
Intuitive Surgical Financial Statements 2011-2026 | ISRG
Annual Financial Statements Intuitive Surgical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
171 B | 203 B | 133 B | 87 B | 103 B | 86.2 B | 65.9 B | 57.8 B | 47.8 B | 26.4 B | 20.1 B | 18.2 B | 16.7 B | 22.8 B | 17.9 B |
Shares |
357 M | 355 M | 351 M | 356 M | 356 M | 351 M | 115 M | 114 M | 112 M | 115 M | 111 M | 111 M | 120 M | 119 M | 118 M |
Historical Prices |
479 | 572 | 379 | 245 | 290 | 246 | 178 | 183 | 142 | 81.9 | 62.6 | 55.6 | 49.4 | 56.7 | 56.8 |
Net Income |
2.86 B | 2.32 B | 1.8 B | 1.32 B | 1.7 B | 1.06 B | 1.38 B | 1.13 B | 660 M | 736 M | 589 M | 419 M | 671 M | 657 M | 495 M |
Revenue |
10.1 B | 8.35 B | 7.12 B | 6.22 B | 5.71 B | 4.36 B | 4.48 B | 3.72 B | 3.13 B | 2.7 B | 2.38 B | 2.13 B | 2.27 B | 2.18 B | 1.76 B |
Cost of Revenue |
3.42 B | 2.72 B | 2.39 B | 2.03 B | 1.75 B | 1.5 B | 1.37 B | 1.12 B | 935 M | 814 M | 806 M | 718 M | 671 M | 608 M | 484 M |
Gross Profit |
6.64 B | 5.63 B | 4.73 B | 4.2 B | 3.96 B | 2.86 B | 3.11 B | 2.6 B | 2.19 B | 1.89 B | 1.58 B | 1.41 B | 1.59 B | 1.57 B | 1.27 B |
Operating Income |
2.95 B | 2.35 B | 1.77 B | 1.58 B | 1.82 B | 1.05 B | 1.37 B | 1.2 B | 1.06 B | 950 M | 740 M | 545 M | 852 M | 878 M | 695 M |
EBITDA |
3.55 B | 2.79 B | 2.15 B | 1.9 B | 2.1 B | 1.27 B | 1.58 B | 1.32 B | 1.15 B | 1.04 B | 830 M | 619 M | 920 M | 936 M | 741 M |
Operating Expenses |
3.7 B | 3.29 B | 2.96 B | 2.62 B | 2.14 B | 1.81 B | 1.74 B | 1.4 B | 1.14 B | 945 M | 838 M | 869 M | 742 M | 692 M | 579 M |
General and Administrative Expenses |
2.38 B | 2.14 B | 1.96 B | 1.74 B | 1.47 B | 1.22 B | 1.18 B | 987 M | 811 M | 705 M | 640 M | 691 M | 574 M | 522 M | 439 M |
All numbers in USD currency
Quarterly Income Statement Intuitive Surgical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
357 M | 358 M | 358 M | 357 M | 356 M | 355 M | 354 M | 352 M | 352 M | 351 M | 350 M | 350 M | 355 M | - | 358 M | 358 M | 357 M | 119 M | 354 M | 353 M | 352 M | 117 M | 116 M | 116 M | 115 M | 115 M | 115 M | 114 M | 114 M | 114 M | 113 M | 112 M | 112 M | 111 M | 112 M | 116 M | 116 M | 38.3 M | 37.7 M | 37.4 M | 37.3 M | 36.9 M | 36.7 M | 36.6 M | 36.1 M | 36.9 M | 38.3 M | 38.2 M | 38.6 M | 39.9 M | 40.3 M | 40.2 M | 39.9 M | 39.9 M | 39.5 M | 39.3 M | 39.1 M | 39.2 M | 39.1 M |
Net Income |
704 M | 658 M | 698 M | - | 565 M | 527 M | 545 M | - | 416 M | 421 M | 355 M | - | 324 M | - | 366 M | 381 M | 380 M | 517 M | 426 M | 365 M | 314 M | 68 M | 314 M | 358 M | 397 M | 318 M | 306 M | 292 M | 292 M | 255 M | 288 M | -31.5 M | 299 M | 223 M | 181 M | 204 M | 211 M | 184 M | 136 M | 190 M | 167 M | 134 M | 97 M | 147 M | 124 M | 104 M | 44.3 M | 166 M | 157 M | 159 M | 189 M | 175 M | 183 M | 155 M | 144 M | 151 M | 122 M | 117 M | 104 M |
Revenue |
2.51 B | 2.44 B | 2.25 B | - | 2.04 B | 2.01 B | 1.89 B | - | 1.74 B | 1.76 B | 1.7 B | - | 1.56 B | - | 1.49 B | 1.55 B | 1.4 B | 1.46 B | 1.29 B | 1.33 B | 1.08 B | 852 M | 1.1 B | 1.28 B | 1.13 B | 1.1 B | 974 M | 1.05 B | 921 M | 909 M | 848 M | 892 M | 806 M | 759 M | 680 M | 757 M | 683 M | 670 M | 594 M | 676 M | 590 M | 586 M | 532 M | 605 M | 550 M | 512 M | 465 M | 576 M | 499 M | 578 M | 611 M | 609 M | 538 M | 536 M | 495 M | 497 M | 447 M | 426 M | 388 M |
Cost of Revenue |
843 M | 822 M | 796 M | - | 664 M | 637 M | 645 M | - | 576 M | 584 M | 583 M | - | 505 M | - | 478 M | - | 432 M | 440 M | 390 M | - | 353 M | 349 M | 361 M | - | 343 M | 340 M | 304 M | - | 279 M | 277 M | 254 M | - | 239 M | 229 M | 210 M | - | 196 M | 199 M | 190 M | - | 194 M | 200 M | 195 M | - | 190 M | 168 M | 149 M | - | 142 M | 173 M | 177 M | - | 148 M | 150 M | 139 M | - | 121 M | 119 M | 109 M |
Gross Profit |
1.66 B | 1.62 B | 1.46 B | - | 1.37 B | 1.37 B | 1.25 B | - | 1.17 B | 1.17 B | 1.11 B | - | 1.05 B | - | 1.01 B | 1.06 B | 971 M | 1.02 B | 903 M | 896 M | 724 M | 503 M | 738 M | 896 M | 786 M | 759 M | 670 M | 736 M | 642 M | 632 M | 594 M | 634 M | 568 M | 530 M | 470 M | 527 M | 487 M | 471 M | 405 M | 459 M | 396 M | 386 M | 337 M | 393 M | 361 M | 344 M | 315 M | 398 M | 357 M | 405 M | 434 M | 438 M | 390 M | 386 M | 356 M | 363 M | 326 M | 307 M | 279 M |
Operating Income |
760 M | 743 M | 578 M | - | 577 M | 567 M | 469 M | - | 466 M | 463 M | 388 M | - | 399 M | - | 408 M | - | 443 M | 511 M | 417 M | - | 270 M | 80.6 M | 283 M | - | 366 M | 359 M | 252 M | - | 313 M | 277 M | 277 M | - | 281 M | 260 M | 193 M | - | 256 M | 245 M | 179 M | - | 190 M | 174 M | 130 M | - | 159 M | 143 M | 56.6 M | - | 174 M | 218 M | 251 M | - | 211 M | 225 M | 193 M | - | 179 M | 168 M | 148 M |
EBITDA |
763 M | 747 M | 582 M | - | 581 M | 572 M | 474 M | - | 471 M | 468 M | 393 M | - | 407 M | - | 414 M | - | 449 M | 519 M | 482 M | - | 430 M | 183 M | 334 M | - | 474 M | 427 M | 284 M | - | 390 M | 327 M | 300 M | - | 342 M | 300 M | 212 M | - | 310 M | 281 M | 197 M | - | 236 M | 203 M | 144 M | - | 197 M | 168 M | 68.9 M | - | 207 M | 240 M | 262 M | - | 237 M | 240 M | 201 M | - | 200 M | 182 M | 155 M |
Operating Expenses |
903 M | 874 M | 880 M | - | 797 M | 805 M | 776 M | - | 701 M | 709 M | 725 M | - | 653 M | - | 602 M | - | 529 M | 512 M | 486 M | - | 454 M | 422 M | 455 M | - | 420 M | 400 M | 417 M | - | 329 M | 355 M | 317 M | - | 288 M | 270 M | 276 M | - | 231 M | 226 M | 226 M | - | 206 M | 213 M | 206 M | - | 202 M | 201 M | 259 M | - | 182 M | 187 M | 183 M | - | 179 M | 161 M | 163 M | - | 147 M | 138 M | 130 M |
General and Administrative Expenses |
573 M | 561 M | 563 M | - | 511 M | 525 M | 492 M | - | 452 M | 464 M | 480 M | - | 436 M | - | 391 M | - | 363 M | 350 M | 326 M | - | 299 M | 279 M | 308 M | - | 284 M | 279 M | 273 M | - | 221 M | 260 M | 222 M | - | 204 M | 186 M | 203 M | - | 168 M | 171 M | 173 M | - | 155 M | 163 M | 162 M | - | 154 M | 161 M | 216 M | - | 139 M | 146 M | 142 M | - | 129 M | 121 M | 124 M | - | 111 M | 106 M | 99.1 M |
All numbers in USD currency
Main types of financial statements Intuitive Surgical ISRGFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Intuitive Surgical plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
The Cooper Companies
COO
|
$ 70.49 | 0.36 % | $ 14 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.13 | -3.93 % | $ 228 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
ICU Medical
ICUI
|
$ 129.4 | -0.41 % | $ 3.19 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
LeMaitre Vascular
LMAT
|
$ 109.99 | 1.97 % | $ 2.49 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 10.5 | -0.94 % | $ 25.5 M | ||
|
Masimo Corporation
MASI
|
$ 178.69 | 0.14 % | $ 9.52 B | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
Merit Medical Systems
MMSI
|
$ 67.55 | -0.85 % | $ 4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Envista Holdings Corporation
NVST
|
$ 26.03 | 0.81 % | $ 4.37 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Nephros
NEPH
|
$ 3.05 | -1.93 % | $ 31.7 M | ||
|
Haemonetics Corporation
HAE
|
$ 56.66 | -3.08 % | $ 2.85 B | ||
|
Baxter International
BAX
|
$ 16.72 | 0.57 % | $ 8.58 B | ||
|
Pro-Dex
PDEX
|
$ 49.99 | 4.25 % | $ 164 M | ||
|
Pulse Biosciences
PLSE
|
$ 21.29 | 1.72 % | $ 1.43 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
OraSure Technologies
OSUR
|
$ 3.06 | -0.65 % | $ 225 M | ||
|
AngioDynamics
ANGO
|
$ 10.63 | -0.75 % | $ 434 M | ||
|
AtriCure
ATRC
|
$ 29.61 | -0.57 % | $ 1.41 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.69 | 0.94 % | $ 200 M | ||
|
iRhythm Technologies
IRTC
|
$ 118.69 | 0.47 % | $ 3.8 B | ||
|
BioLife Solutions
BLFS
|
$ 19.7 | 2.76 % | $ 908 M | ||
|
Repligen Corporation
RGEN
|
$ 116.3 | -0.04 % | $ 6.48 M | ||
|
Milestone Scientific
MLSS
|
$ 0.29 | 3.78 % | $ 23.1 M | ||
|
electroCore
ECOR
|
$ 6.17 | 0.65 % | $ 52.3 K | ||
|
ResMed
RMD
|
$ 228.19 | 0.1 % | $ 33.3 B | ||
|
Retractable Technologies
RVP
|
$ 0.72 | -0.04 % | $ 21.6 M | ||
|
Glaukos Corporation
GKOS
|
$ 105.23 | -1.51 % | $ 5.1 B | ||
|
Microbot Medical
MBOT
|
$ 2.5 | -0.79 % | $ 25.5 M | ||
|
STAAR Surgical Company
STAA
|
$ 18.97 | 2.49 % | $ 940 M | ||
|
STERIS plc
STE
|
$ 221.73 | 0.33 % | $ 21.9 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Stereotaxis
STXS
|
$ 1.8 | -2.17 % | $ 164 M | ||
|
Teleflex Incorporated
TFX
|
$ 106.56 | 0.67 % | $ 4.75 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 155.92 | -0.19 % | $ 44.9 B | ||
|
Repro Med Systems
KRMD
|
$ 4.4 | -0.68 % | $ 203 M | ||
|
Utah Medical Products
UTMD
|
$ 63.8 | -2.04 % | $ 232 M | ||
|
West Pharmaceutical Services
WST
|
$ 245.27 | 1.6 % | $ 17.7 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.47 | -0.65 % | $ 2.29 B | ||
|
Alcon
ALC
|
$ 74.24 | 0.13 % | $ 40.4 B |